129 related articles for article (PubMed ID: 38085101)
1. Differential effects of dietary polyphenols on oral pharmacokinetics of cyclin-dependent kinase inhibitors in rats: a mechanistic framework for in vitro-in vivo extrapolation.
Patil PH; Desai MP; Birangal S; Gautham Shenoy G; Channabasavaiah JP
J Pharm Pharmacol; 2024 Jan; 76(2):93-105. PubMed ID: 38085101
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulation and in vitro evaluation of herb-drug interactions involving dietary polyphenols and CDK inhibitors in breast cancer chemotherapy.
Patil PH; Birangal S; Shenoy GG; Rao M; Kadari S; Wankhede A; Rastogi H; Sharma T; Pinjari J; Puralae Channabasavaiah J
Phytother Res; 2022 Oct; 36(10):3988-4001. PubMed ID: 35778986
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
[TBL] [Abstract][Full Text] [Related]
4. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
Choi JS; Piao YJ; Kang KW
Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
[TBL] [Abstract][Full Text] [Related]
5. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.
Lee CK; Ki SH; Choi JS
Biopharm Drug Dispos; 2011 May; 32(4):245-51. PubMed ID: 21506134
[TBL] [Abstract][Full Text] [Related]
7. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
8. Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats.
Zhao Q; Wei J; Zhang H
Xenobiotica; 2019 May; 49(5):563-568. PubMed ID: 29768080
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases.
Palle S; Neerati P
Pharmacol Rep; 2017 Apr; 69(2):365-370. PubMed ID: 28189992
[TBL] [Abstract][Full Text] [Related]
11. Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism.
Shang H; Wang Z; Ma H; Sun Y; Ci X; Gu Y; Liu C; Si D
Pharm Biol; 2021 Dec; 59(1):200-208. PubMed ID: 33595422
[TBL] [Abstract][Full Text] [Related]
12. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
13. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
14. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
Choi JS; Choi I; Choi DH
Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
[TBL] [Abstract][Full Text] [Related]
15. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
Choi SJ; Shin SC; Choi JS
Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
[TBL] [Abstract][Full Text] [Related]
16. Determination of effective concentrations of drug absorption enhancers using in vitro and ex vivo models.
Kheoane PS; Enslin GM; Tarirai C
Eur J Pharm Sci; 2021 Dec; 167():106028. PubMed ID: 34601070
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Oral Bioavailability of Domperidone with Piperine in Male Wistar Rats: Involvement of CYP3A1 and P-gp Inhibition.
Athukuri BL; Neerati P
J Pharm Pharm Sci; 2017; 20():28-37. PubMed ID: 28459658
[TBL] [Abstract][Full Text] [Related]
18. Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats.
Yang Y; Hu N; Gao XJ; Li T; Yan ZX; Wang PP; Wei B; Li S; Zhang ZJ; Li SL; Yan R
J Ethnopharmacol; 2021 Jan; 265():113251. PubMed ID: 32810615
[TBL] [Abstract][Full Text] [Related]
19. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.
Sun X; Tang S; Hou B; Duan Z; Liu Z; Li Y; He S; Wang Q; Chang Q
BMC Gastroenterol; 2021 Jan; 21(1):2. PubMed ID: 33407159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
